Last $113.32 USD
Change Today -5.98 / -5.02%
Volume 10.9M
As of 4:30 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $128.96
52 Week Low
06/6/13 - $94.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

20,000 Employees
Last Reported Date: 02/24/14
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $845.9K
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Compensation as of Fiscal Year 2013.

amgen inc (AMGN) Key Developments

Amgen Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Year 2014

Amgen Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenues increased 7% to $4.52 billion in first quarter, with 5% product sales growth driven by Kyprolis (carfilzomib), XGEVA (denosumab), Prolia (denosumab) and Neulasta (pegfilgrastim). Operating income was $1,364 million against $1,442 million a year ago. Income before income tax was $1,204 million against $1,343 million a year ago. Net income was $1,073 million against $1,434 million a year ago. Diluted EPS was $1.40 against $1.88 a year ago. Adjusted operating income was $1,860 million against $1,572 million a year ago. Adjusted income before income tax was $1,700 million against $1,485 million a year ago. Adjusted net income was $1,438 million or $1.87 per diluted share against $1,498 million or $1.96 per diluted share a year ago. Cash flows from operations were $1,142 million against $1,049 million a year ago. Capital expenditures were $172 million against $158 million a year ago. Despite 14% growth in pretax income, net income declined 4% and earnings per share declined 5% due to favorable tax items in the year-ago period. The company generated $1 billion in free cash flow in the first quarter of 2014, a year-over-year increase of 9% and ahead of revenue growth. For the year 2014, the company expected EPS in a range of $6.65 to $6.95 on revenue of $19.2 billion to $19.6 billion. Adjusted diluted EPS guidance will be in the range of $7.90 to $8.20. Adjusted tax rate will be in the range of 15% to 16%. Capital expenditures will be approximately $800 million. Guidance on tax and capital expenditures remains unchanged.

Amgen Inc. Announces Earnings Results for the Full Year of 2013

Amgen Inc. announced earnings results for the full year of 2013. For the period, the company reported growth of revenues by 8% over 2012 to $18.7 billion and year-over-year adjusted earnings per share grew 17% in 2013, far exceeding the company's peer group median average of 3% for each measure. The adjusted net income grew by 14% to $5.8 billion.

Amgen Inc. to Report Q1, 2014 Results on Apr 22, 2014

Amgen Inc. announced that they will report Q1, 2014 results at 5:00 PM, Eastern Standard Time on Apr 22, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $113.32 USD -5.98

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $50.14 USD +0.13
AstraZeneca PLC 4,043 GBp +82.50
Bristol-Myers Squibb Co $50.95 USD -0.04
Eli Lilly & Co $59.56 USD -0.47
Novo Nordisk A/S kr243.30 DKK -1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AMGN Industry Range
Price/Earnings 18.0x
Price/Sales 4.8x
Price/Book 4.1x
Price/Cash Flow 17.8x
TEV/Sales 2.1x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at